Swiss pharmaceutical company Novartis has announced it will take a charge of $590 million (SFr573 million) in the third quarter as it discontinued two drugs.This content was published on October 5, 2010 - 09:57
But it added that the charge would be partially offset by a $390 million gain to be booked in the fourth quarter from its divestment of overactive bladder treatment Enablex to Warner Chilcott.
Novartis said in a statement it was stopping Mycograb, an antifungal agent, resulting in a charge of about $360 million.
The Basel-based firm also said it and Human Genome Sciences had decided to stop development of albinterferon alfa-2b for the treatment of adults with chronic hepatitis C, resulting in a write-down of some $230 million.
The reason cited was feedback from regulators in Europe and the United States, as well as new study data,
Albinterferon alfa-2b is known by its brand name Joulferon in Europe and Zalbin in the US.
This article was automatically imported from our old content management system. If you see any display errors, please let us know: firstname.lastname@example.org